Myeloproliferative Disorders Drugs Market Size, Share & Trends Analysis Report By Indication (Ph- MPN (MF, PV, ET), Ph+ CML), By Major Markets, Competitive Landscape, And Segment Forecasts, 2018 - 2023

Table of Contents

Chapter 1 Research Methodology
                  1.1. Information Procurement
                  1.2. Information or Data Analysis
                      1.2.1 Market Formulation & Validation
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
                  3.1. Disease Primer
                  3.2. Epidemiology
Chapter 4 Global Myeloproliferative Disorders Drugs Market Overview
                  4.1 Market by Indication
                  4.2 Market Size and Forecast 2017 - 2023
                  4.3 Market Share Distribution, by Company 2017 - 2023
                  4.4 Market Dynamics and Brand Strategies
                  4.5 Patent Expiry Analysis
                  4.6 Myeloproliferative Disorders Market: Drivers and Restraints
                      4.6.1 Drivers
                      4.6.2 Challenges
                  4.7 M&A, Deal Landscape (2013 - 2018 YTD)
                      4.7.1 Mergers & Acquisitions
                      4.7.2 Deals Landscape
                  4.8 Reimbursement Scenario
                  4.9 Myeloproliferative Disorders Market: Sector SWOT
Chapter 5 Myeloproliferative Disorders Market: Pipeline Intelligence
                  5.1. Pipeline Landscape
                      5.1.1 Leading Drugs in Development
                      5.1.2 Key R&D Trends
                  5.2 Pipeline Landscape
                      5.2.1 Late-Stage Pipeline and Sales Forecast
                      5.2.2 Profiles of Disruptive Drugs
                  5.3 Global Pipeline Forecast
Chapter 6 Company Profiles
                  6.1 Novartis
                      6.1.1 Company Overview
                      6.1.2 Current Product Portfolio
                      6.1.3 Product Forecast Sales Through 2023
                      6.1.4 Strategic Initiatives
                          6.1.4.1 Key Company News Flow
                      6.1.5 Pipeline Analysis & Overview
                      6.1.6 SWOT
                  6.2 Bristol-Myers Squibb
                      6.2.1 Company Overview
                      6.2.2 Current Product Portfolio
                      6.2.3 Product Forecast Sales Through 2023
                      6.2.4 Strategic Initiatives
                          6.2.4.1 Key Company News Flow
                      6.2.5 Pipeline Analysis & Overview
                      6.2.6 SWOT
                  6.3 Pfizer
                      6.3.1 Company Overview
                      6.3.2 Current Product Portfolio
                      6.3.3 Product Forecast Sales Through 2023
                      6.3.4 Strategic Initiatives
                          6.3.4.1 Key Company News Flow
                      6.3.5 Pipeline Analysis & Overview
                      6.3.6 SWOT
                  6.4 Takeda
                      6.4.1 Company Overview
                      6.4.2 Current Product Portfolio
                      6.4.3 Product Forecast Sales Through 2023
                      6.4.4 Strategic Initiatives
                          6.4.4.1 Key Company News Flow
                      6.4.5 SWOT
                  6.5 Inctye
                      6.5.1 Company Overview
                      6.5.2 Current Product Portfolio
                      6.5.3 Product Forecast Sales Through 2023
                      6.5.4 Strategic Initiatives
                          6.5.4.1 Key Company News Flow
                      6.5.5 Pipeline Analysis & Overview
                      6.5.6 SWOT
                  6.6 Teva
                      6.6.1 Company Overview
                      6.6.2 Current Product Portfolio
                      6.6.3 Product Forecast Sales Through 2023
                      6.6.4 Strategic Initiatives
                          6.6.4.1 Key Company News Flow
                      6.6.5 SWOT
Chapter 7 Market Outlook
                  7.1 What the Future Holds
                  7.2 The Winners and Losers
                      7.2.1 Winners
                      7.2.2 Losers
                  7.3 Emerging Companies & Technology Platforms
                  7.4 The Road Ahead

List of Tables

TABLE 1 Marketed Drugs for Myeloproliferative Disorders
TABLE 2 Sales Performance by Indication, 2017 - 23
TABLE 3 Ph+ CML Sales Performance by Country, in $ million, 2017 - 2023
TABLE 4 Ph- MPNs Sales Performance by Country, in $ million, 2017 - 2023
TABLE 5 U.S. Ph- MPNs Sales Performance, in $ million, 2017 - 2023
TABLE 6 U.K. Ph- MPNs Sales Performance, in $ million, 2017 - 2023
TABLE 7 Germany Ph- MPNs Sales Performance, in $ million, 2017 - 2023
TABLE 8 France Ph- MPNs Sales Performance, in $ million, 2017 - 2023
TABLE 9 Italy Ph- MPNs Sales Performance, in $ million, 2017 - 2023
TABLE 10 Spain Ph- MPNs Sales Performance, in $ million, 2017 - 2023
TABLE 11 Japan Ph- MPNs Sales Performance, in $ million, 2017 - 2023
TABLE 12 Patents Expiry for Current Myeloproliferative Disorders Drugs
TABLE 13 Annual price estimates of drugs approved for the treatment of CML, by Country
TABLE 14 R&D Pipeline Overview
TABLE 15 Late-Stage Pipeline
TABLE 16 Asciminib (ABL001)
TABLE 17 NiCord
TABLE 18 Pacritinib
TABLE 19 Luspatercept (ACE-536)
TABLE 20 Pipeline Forecast
TABLE 21 Novartis Sales Forecast, 2017 - 2023
TABLE 22 Novartis Pipeline
TABLE 23 Bristol-Myers Squibb Sales Forecast, 2017 - 2023
TABLE 24 Bristol-Myers Squibb Pipeline
TABLE 25 Pfizer Sales Forecast, 2017 - 2023
TABLE 26 Pfizer Pipeline
TABLE 27 Takeda Sales Forecast, 2017 - 2023
TABLE 28 Incyte Sales Forecast, 2017 - 2023
TABLE 29 Incyte Pipeline
TABLE 30 Teva Sales Forecast, 2017 - 2023

List of Figures

FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modeling for market share assessment
FIG. 7 Myeloproliferative Disorders Market Share, by Treatment Type, 2017 & 23
FIG. 8 Regional Market Size, 2017 & 2023
FIG. 9 U.S. Myeloproliferative Disorders Drugs Market, $ million (2017 - 23)
FIG. 10 U.K. Myeloproliferative Disorders Drugs Market, $ million (2017 - 23)
FIG. 11 Germany Myeloproliferative Disorders Drugs Market, $ million (2017 - 23)
FIG. 12 France Myeloproliferative Disorders Drugs Market, $ million (2017 - 23)
FIG. 13 Italy Myeloproliferative Disorders Drugs Market, $ million (2017 - 23)
FIG. 14 Spain Myeloproliferative Disorders Drugs Market, $ million (2017 - 23)
FIG. 15 Japan Myeloproliferative Disorders Drugs Market, $ million (2017 - 23)
FIG. 16 Ph+ CML Market Shares Distribution, 2017 & 2023
FIG. 17 Ph- MPNs Market Shares Distribution, 2017 & 2023
FIG. 18 Myeloproliferative Disorders SWOT
FIG. 19 Myeloproliferative Disorders Pipeline Distribution
FIG. 20 Novartis Myeloproliferative Disorders Sales Forecast
FIG. 21 Novartis SWOT Analysis
FIG. 22 Bristol-Myers Squibb Myeloproliferative Disorders Sales Forecast
FIG. 23 Bristol-Myers Squibb SWOT Analysis
FIG. 24 Pfizer Myeloproliferative Disorders Sales Forecast
FIG. 25 Pfizer SWOT Analysis
FIG. 26 Takeda Myeloproliferative Disorders Sales Forecast
FIG. 27 Takeda SWOT Analysis
FIG. 28 Incyte Myeloproliferative Disorders Sales Forecast
FIG. 29 Incyte SWOT Analysis
FIG. 30 Teva Myeloproliferative Disorders Sales Forecast
FIG. 31 Teva SWOT Analysis